TABLE 2.

Ex vivo expression of chemokine receptors by peripheral blood leukocyte subsets in the patient with combined neurotropic and viscerotropic disease following 17D YF vaccination

Cell typeChemokine receptorValuea
RVPatient
MonocytesCXCR48.34 ± 2.338.7
CXCR310.70 ± 2.549.25
CCR58.91 ± 3.179.80
CCR29.93 ± 4.1210.29
CD4+ T cellsCXCR44.50 ± 1.024.70
CXCR326.68 ± 4.67↓4.33**
CCR53.34 ± 1.713.75
CCR22.80 ± 0.603.26
CCR32.89 ± 0.813.46
CD8+ T cellsCXCR47.99 ± 1.995.06
CXCR332.73 ± 6.50↓5.59**
CCR55.38 ± 1.743.84
CCR24.65 ± 1.713.53
CCR33.93 ± 0.733.93
  • a RV, RVs for chemokine receptor expression by peripheral blood leukocyte subsets observed 15 days after 17DD vaccination in the absence of adverse reactions (n = 10); Patient, values for chemokine receptor expression by peripheral blood leukocyte subset frequencies observed in the patient with combined neurotropic and viscerotropic adverse events temporally associated with 17D vaccination YF. The results are expressed as the mean percentage ± SD of positive cells unless MFI is indicated, in which case the results are expressed as the mean MFI ± SD for the expression of a given cell surface marker within gated lymphocytes. *, statistical significance was considered when the values for the patient were outside of the RV range (mean ± 2 SDs); **, additional statistical significance was considered when the values for the patient were outside the range of 0.5 to 2.0 times the mean RVs. ↑ and ↓, increase and decrease in the values, respectively, in comparison to the RVs.